SERPINA1 and Alpha-1 Antitrypsin Deficiency: Genetic Testing Guide

Alpha-1 antitrypsin deficiency is one of the most common genetic conditions you have never heard of. Affecting approximately 1 in 1,500 to 1 in 3,500 individuals of European ancestry, this SERPINA1-related disorder damages both lungs and liver through a single mechanism: the failure to produce a protective protein that keeps destructive enzymes in check (Stoller & Aboussouan, 2012).

For people who develop symptoms, the consequences are severe: early-onset emphysema and COPD, often before age 45, and progressive liver disease that can lead to cirrhosis. Yet most carriers remain unaware of their status until serious complications arise. Genetic testing offers the opportunity to identify risk decades before symptoms develop, enabling protective measures that can significantly alter disease trajectory.

What Is Alpha-1 Antitrypsin Deficiency?

Alpha-1 antitrypsin deficiency is an autosomal recessive disorder caused by mutations in the SERPINA1 gene on chromosome 14. This gene encodes alpha-1 antitrypsin (AAT), a protein produced primarily in the liver that circulates through the bloodstream to the lungs. Its critical function: neutralizing neutrophil elastase, an enzyme released by immune cells to fight infection but capable of destroying lung tissue when unchecked (Crystal, 1990).

In healthy individuals, AAT binds to neutrophil elastase and inactivates it, protecting the delicate alveolar walls that enable oxygen exchange. When AAT is deficient or dysfunctional, neutrophil elastase persists, gradually digesting lung tissue and producing the characteristic panacinar emphysema seen in affected patients (Brantly et al., 1988).

The condition follows autosomal recessive inheritance, meaning both copies of the SERPINA1 gene must carry mutations for severe deficiency to occur. Heterozygotes (single mutation carriers) typically produce 60-80% of normal AAT levels, usually sufficient to prevent lung disease but occasionally associated with liver abnormalities (Lomas & Mahadeva, 2002).

The SERPINA1 Variants: From M to Z and Beyond

The SERPINA1 gene is highly polymorphic, with over 150 variants identified. These are classified by their electrophoretic mobility: M (normal), S (slow), and Z (very slow), with the M variant being the wild-type normal allele (Brantly et al., 1988).

The Z Allele (Glu342Lys): The most common severe deficiency variant, present in approximately 2-3% of European populations. A single amino acid substitution (glutamic acid to lysine at position 342) causes the protein to misfold and polymerize within hepatocytes. Only 10-15% of normal AAT reaches circulation; the remainder accumulates in liver cells, causing both lung deficiency and potential liver toxicity (Sifers, 1992).

The S Allele (Glu264Val): Less severe than Z but still clinically significant. Present in approximately 2-4% of Europeans, it produces roughly 60% of normal AAT levels. Homozygous SS individuals usually avoid lung disease, but compound heterozygotes (SZ) have intermediate deficiency and elevated risk (Fagerhol & Cox, 1981).

Rare Deficiency Variants: Dozens of other variants cause varying degrees of deficiency, from Null alleles (producing no protein) to dysfunctional variants where the protein is made but does not function properly. The I allele, common in Scandinavia, and the Mmalton variant both cause substantial deficiency with different molecular mechanisms (Hersh et al., 2013).

Clinical Manifestations: Lung and Liver

Pulmonary Disease

The classic presentation involves early-onset emphysema, typically developing in the third to fifth decade of life for ZZ homozygotes. Several features distinguish AAT deficiency-related COPD from smoking-induced disease:

Distribution: Panacinar emphysema affecting the lower lung zones predominates, in contrast to the centrilobular upper-lobe pattern seen in smokers (Brantly et al., 1988).

Age of Onset: Symptoms often begin in the 30s or 40s, decades earlier than typical COPD. Shortness of breath with exertion, chronic cough, and recurrent respiratory infections are common presenting complaints (Stoller & Aboussouan, 2012).

Progression: Without intervention, lung function declines more rapidly than in typical COPD. Forced expiratory volume in one second (FEV1) may decrease by 50-100 mL annually in ZZ individuals, compared to 30-50 mL in smoking-related disease (Dowson et al., 2000).

Exacerbating Factors: Smoking accelerates lung damage dramatically. ZZ smokers develop severe COPD approximately 10-15 years earlier than non-smoking ZZ individuals, with many requiring lung transplantation by age 50 (Silverman et al., 1989).

Hepatic Disease

While lung disease results from deficiency, liver disease stems from polymerization and accumulation of abnormal AAT within hepatocytes. Clinical manifestations include:

Neonatal Cholestasis: Approximately 10% of ZZ infants present with prolonged jaundice and cholestatic hepatitis. Most recover, but some progress to pediatric cirrhosis requiring transplantation (Sveger, 1976).

Adult Liver Disease: Cirrhosis and hepatocellular carcinoma develop in 30-40% of ZZ adults by age 50. The mechanism involves ER stress, autophagy dysfunction, and apoptosis triggered by polymer accumulation (Perlmutter, 2006).

Heterozygote Risk: Even MZ carriers have elevated liver disease risk compared to MM individuals, though absolute risk remains low. The combination of AAT accumulation with other insults (alcohol, viral hepatitis) appears synergistic (Rudnick & Perlmutter, 2005).

Genetic Testing: Who Should Be Tested?

Guidelines from the American Thoracic Society and European Respiratory Society recommend testing for (Sandhaus et al., 2016):

• All individuals with COPD or asthma with incompletely reversible airflow obstruction
• Adults with unexplained liver disease, particularly if cholestatic
• Adults with necrotizing panniculitis, a rare dermatologic manifestation
• Siblings of known AAT deficiency patients (cascade screening)
• Individuals with persistent obstructive pattern on spirometry and no smoking history

The availability of direct-to-consumer genetic testing and raw data analysis has expanded access beyond clinical settings. Individuals with 23andMe or AncestryDNA data can check their SERPINA1 status through third-party analysis tools.

Interpreting Genetic Test Results

Genetic testing identifies the specific SERPINA1 variants present. Results are typically reported as a genotype (e.g., ZZ, MZ, MS, MM):

MM: Normal. Two normal alleles, AAT levels 100% of normal.

MZ: Carrier. One Z allele, AAT levels 60-80% of normal. Generally no lung disease risk, slight liver disease elevation.

MS: Carrier. One S allele, AAT levels 80% of normal. Minimal clinical significance.

SZ: Compound heterozygote. AAT levels 40-60% of normal. Moderate deficiency, lung disease risk if smoker or exposed to occupational dust.

ZZ: Severe deficiency. AAT levels 10-15% of normal. High risk for lung and liver disease without intervention.

Null variants: Produce no AAT protein. Similar to ZZ for lung disease but no liver disease risk (no polymer accumulation).

Serum AAT level testing provides complementary information. Levels below 11 micromolar (approximately 57 mg/dL) indicate severe deficiency and warrant further evaluation (Sandhaus et al., 2016).

Management and Treatment Options

Augmentation Therapy

The cornerstone of treatment for ZZ individuals with lung disease is intravenous augmentation therapy - weekly or biweekly infusions of purified human AAT. This raises serum levels to protective thresholds and slows lung function decline (Stockley et al., 2010).

Clinical trials demonstrate reduced rate of FEV1 decline, fewer exacerbations, and decreased mortality in treated patients. However, augmentation therapy does not treat liver disease and is extremely expensive, costing $100,000-$150,000 annually in the United States (Stoller & Aboussouan, 2012).

Lifestyle Interventions

Smoking Cessation: The single most important intervention. ZZ smokers lose lung function 3-5 times faster than ZZ non-smokers. Never smoking essentially eliminates the risk of severe early-onset COPD (Silverman et al., 1989).

Environmental Protection: Avoiding occupational dust, chemical fumes, and air pollution reduces lung injury. Indoor air quality improvements and air filtration help.

Alcohol Moderation: For individuals with liver involvement, alcohol abstinence or severe restriction slows progression.

Emerging Therapies

Research into small molecule chaperones that prevent Z-AAT polymerization is ongoing. If successful, such therapies could theoretically address both lung deficiency (by allowing more functional protein to exit the liver) and liver disease (by preventing polymer accumulation) (Burrows et al., 2000).

Gene therapy approaches aim to introduce functional SERPINA1 genes directly into airway epithelial cells, bypassing the liver entirely. Early-phase clinical trials are underway.

Family Planning and Genetic Counseling

For ZZ individuals, all offspring will be carriers (MZ) if the partner is MM. If both parents carry Z alleles, each child has a 25% chance of being ZZ, 50% chance of being MZ, and 25% chance of being MM.

Preimplantation genetic testing and prenatal diagnosis are available for at-risk couples. Genetic counseling helps families understand recurrence risks and reproductive options (Stoller & Aboussouan, 2012).

Key Takeaways

• Alpha-1 antitrypsin deficiency affects 1 in 1,500-3,500 people, making it one of the most common serious genetic conditions
• The Z allele (Glu342Lys) is the most common severe deficiency variant in European populations
• ZZ homozygotes develop early-onset COPD and are at risk for liver cirrhosis
• Smoking accelerates lung damage dramatically; never smoking is the most protective intervention
• Genetic testing identifies at-risk individuals before symptoms develop
• Augmentation therapy slows lung disease progression but does not treat liver involvement
• Siblings of affected individuals should be tested (cascade screening)

Explore Your Own Genetics

Upload your raw DNA data to GenomeInsight and get instant, research-backed insights into your SERPINA1 genotype and alpha-1 antitrypsin status. Know your risk before symptoms develop.

• Upload your DNA data →
• Learn how it works →
• See full pricing →
• Subscribe to our newsletter →

References

Brantly, M. L., Paul, L. D., Miller, B. H., Falk, R. T., Wu, M., & Crystal, R. G. (1988). Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. American Review of Respiratory Disease, 138(2), 327-336. https://doi.org/10.1164/ajrccm/138.2.327

Burrows, J. A., Willis, L. K., & Perlmutter, D. H. (2000). Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proceedings of the National Academy of Sciences, 97(4), 1796-1801. https://doi.org/10.1073/pnas.97.4.1796

Crystal, R. G. (1990). Alpha 1-antitrypsin deficiency, emphysema, and liver disease: Genetic basis and strategies for therapy. Journal of Clinical Investigation, 85(5), 1343-1352. https://doi.org/10.1172/JCI114565

Dowson, L. J., Guest, P. J., Hill, S. L., Holder, R. L., & Stockley, R. A. (2000). High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: Relationship to lung function and health status. European Respiratory Journal, 16(6), 1097-1104. https://doi.org/10.1034/j.1399-3003.2000.0160061097.x

Fagerhol, M. K., & Cox, D. W. (1981). The Pi polymorphism: Genetic, biochemical and clinical aspects of human alpha-1-antitrypsin. Advances in Human Genetics, 11, 1-62.

Hersh, C. P., Dahl, M., Ly, N. P., Berndt, A., Silverman, E. K., & Nordestgaard, B. G. (2013). Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: A meta-analysis. Thorax, 69(9), 842-848. https://doi.org/10.1136/thoraxjnl-2013-203945

Lomas, D. A., & Mahadeva, R. (2002). Alpha1-antitrypsin polymerization and the serpinopathies: Pathobiology and prospects for therapy. Journal of Clinical Investigation, 110(11), 1585-1590. https://doi.org/10.1172/JCI200216782

Perlmutter, D. H. (2006). The role of autophagy in alpha-1-antitrypsin deficiency: A specific cellular response in genetic diseases associated with aggregation-prone proteins. Autophagy, 2(4), 258-263. https://doi.org/10.4161/auto.2895

Rudnick, D. A., & Perlmutter, D. H. (2005). Alpha-1-antitrypsin deficiency: A new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology, 42(3), 514-521. https://doi.org/10.1002/hep.20840

Sandhaus, R. A., Turino, G., Brantly, M. L., Campos, M., Cross, C. E., Goodman, K., ... & Strange, C. (2016). The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstructive Pulmonary Diseases, 3(3), 668-682. https://doi.org/10.15326/jcopdf.3.3.2015.0182

Silverman, E. K., Pierce, J. A., Province, M. A., Rao, D. C., & Campbell, E. J. (1989). Variability of pulmonary function in alpha-1-antitrypsin deficiency: Clinical correlates. Annals of Internal Medicine, 111(12), 982-991. https://doi.org/10.7326/0003-4819-111-12-982

Sifers, R. N. (1992). Intracellular processing of alpha1-antitrypsin. Proceedings of the American Thoracic Society, 7(6), 376-380. https://doi.org/10.1513/pats.200907-083DP

Stockley, R. A., Miravitlles, M., Vogelmeier, C., & Alpha One International Registry. (2010). Augmentation therapy for alpha-1 antitrypsin deficiency: Towards a personalised approach. Orphanet Journal of Rare Diseases, 5, 9. https://doi.org/10.1186/1750-1172-5-9

Stoller, J. K., & Aboussouan, L. S. (2012). A review of alpha1-antitrypsin deficiency. American Journal of Respiratory and Critical Care Medicine, 185(3), 246-259. https://doi.org/10.1164/rccm.201108-1428CI

Sveger, T. (1976). Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. New England Journal of Medicine, 294(24), 1316-1321. https://doi.org/10.1056/NEJM197606172942404

---

Related Reading

• CYP2C19 and clopidogrel pharmacogenomics
• CYP2D6 drug metabolism
• Pharmacogenomics guide
• What to do with your 23andMe raw data
• Cystic fibrosis carrier screening
• Genetic testing benefits